However, in contrast with in vitro data, in vivo studies suggest that MEK-i do not interfere with the anti-tumor activity of T-cell-based therapy [15] or of specific immunomodulatory antibodies targeting PD-1, PD-L1 and CTLA-4 [16]. This evidence concerns the gene CD274 and neoplasm.